For research use only. Not for therapeutic Use.
KGA-2727 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used in diabetes research. By targeting the SGLT2 protein in the kidneys, KGA-2727 reduces glucose reabsorption and increases urinary glucose excretion, helping to lower blood glucose levels. This mechanism makes it a promising therapeutic candidate for managing type 2 diabetes, offering an insulin-independent approach to glycemic control. Additionally, KGA-2727 has been studied for its potential benefits in weight reduction and improving cardiovascular outcomes. Its efficacy and specificity make it a valuable tool for exploring new treatments for diabetes and metabolic disorders.
| Catalog Number | I007497 |
| CAS Number | 666842-36-0 |
| Synonyms | 3-[3-[3-methyl-4-[[5-propan-2-yl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1H-pyrazol-4-yl]methyl]phenoxy]propylamino]propanamide |
| Molecular Formula | C26H40N4O8 |
| Purity | ≥95% |
| InChI | InChI=1S/C26H40N4O8/c1-14(2)21-18(25(30-29-21)38-26-24(35)23(34)22(33)19(13-31)37-26)12-16-5-6-17(11-15(16)3)36-10-4-8-28-9-7-20(27)32/h5-6,11,14,19,22-24,26,28,31,33-35H,4,7-10,12-13H2,1-3H3,(H2,27,32)(H,29,30)/t19-,22-,23+,24-,26+/m1/s1 |
| InChIKey | MDBARDSTXONTFS-MNDUUMEHSA-N |
| SMILES | CC1=C(C=CC(=C1)OCCCNCCC(=O)N)CC2=C(NN=C2OC3C(C(C(C(O3)CO)O)O)O)C(C)C |
